医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Gynesonics Announces First Patient Successfully Treated With Newly Designed Incisionless VizAblate® System for Symptomatic Uterine Fibroids

2014年06月24日 PM08:00
このエントリーをはてなブックマークに追加


 

REDWOOD CITY, Calif.

Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the first treatment of a patient in Cologne, Germany, using the Company’s newly-designed VizAblate® System. VizAblate is the only medical device to integrate ultrasound imaging with radiofrequency ablation in a single handheld device for the treatment of fibroids. The System is minimally invasive and is inserted through the cervix without any need for incisions.

Professor Thomas Römer, M.D., and Ralf Bends, M.D., performed the first procedure with the new VizAblate System at Evangelisches Krankenhaus Köln-Weyertal gGmbH in Cologne, Germany.

“The procedure was straightforward thanks to the unique and improved design of the new VizAblate System,” Ralf Bends said. “The intrauterine ultrasound imaging made the navigation and radiofrequency ablation extremely efficient. The entire system can be mastered with a very achievable and short learning curve. This system may produce a paradigm shift in the way patients are treated for symptomatic uterine fibroids.”

The new VizAblate System has been designed to improve ease-of-use, increase ultrasound resolution, and streamline the graphical user interface. The incision-less procedure preserves the uterus, does not involve laparoscopy or hysteroscopy, and features the industry’s first, exclusive graphically-based ablation sizing guide and safety margin indicator. VizAblate is amenable to an outpatient setting and has short procedure times. VizAblate can ablate larger and deeper fibroids that are not treatable by other transcervical methods.

“Based on our experience, the Gynesonics VizAblate System, which does not require an incision, offers an exciting and less invasive treatment for symptomatic uterine fibroids,” said Professor Römer.

Gynesonics President and CEO Christopher M. Owens noted that this is an encouraging first step towards commercialization of the new system, initiating a broader clinical strategy and demonstrating the tremendous value the VizAblate technology may have for millions of women globally.

According to the medical literature, in the United States, about 70-80 percent of women in the US will develop uterine fibroids by age 50. In addition, approximately 200,000 hysterectomies are performed in the United States each year because of symptomatic fibroids, according to the New England Journal of Medicine.

About Gynesonics

Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the VizAblate® System for the transcervical treatment of symptomatic uterine fibroids under intrauterine ultrasound guidance. VizAblate has received CE Mark approval for commercial sale in the European Union. VizAblate is not available for sale in the United States. Gynesonics is a privately held company with headquarters in Redwood City, CA.

CONTACT

Gynesonics
Chris Owens, 650-216-3860
President and CEO
www.gynesonics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PotNetwork Holdings, Inc.在注册成为SEC报告公司之后发布PCAOB经审计和审核的完整财务报表
  • PotNetwork Holdings, Inc.提交Form 10以成为美国证券交易委员会报告公司
  • レスメド初の最小接触面フルフェイスCPAPマスクAirFit F30を米国とカナダで販売開始
  • Foundation Medicine Announces Strategic Collaboration with Major Pharmaceutical Company
  • Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market